Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences EV-based Diagnostics, Delivery & Therapeutics

Robert Raffai's Biography

Robert Raffai, Professor, University of California-San Francisco

Dr. Raffai earned a PhD degree in Biochemistry within the Lipoprotein Research Group at the University of Ottawa Heart Institute in 1998. He subsequently trained extensively in lipoprotein metabolism and atherosclerosis cardiovascular research as a postdoctoral fellow within the J. David Gladstone Institutes with Dr. Karl H. Weisgraber PhD. He subsequently established a research program focused on exploring the biology of atherosclerosis within the Department of Surgery at UCSF and the VA Medical Center in San Francisco. He is currently Professor of Surgery and Director of the Atherosclerosis Research Laboratory. Dr. Raffai's research program focusses on elucidating the interplay between metabolism and inflammation in atherosclerosis cardiovascular disease and heart failure. Through studies of mouse models developed in his laboratory, Dr. Raffai's team uncovered new pathways through which a protein called ApoE participates in suppressing the progression and enhancing the regression of atherosclerosis. Their discovery linked ApoE metabolism to microRNA-control of immune cell activation and protection from atherosclerosis in mice with hyperlipidemia. A more recent topic in the lab includes to explore how diabetic hyperglycemia alters the biogenesis and regulated release of microRNA in exosomes derived from myeloid cells, and how these exRNA can serve to enhance systemic and vascular inflammation and atherosclerosis. Our goal is to uncover mechanisms to prevent microRNA dysregulation in myeloid cells of diabetic individuals and develop exosomes capable of delivering therapeutic exRNA as novel treatments for diabetic atherosclerosis. To this end, as member of the NIH Extracellular RNA communication Consortium, Dr. Raffai’s team has been developing novel approaches to detect, isolate and engineer exosomes and other biological carriers of exRNA for their use as biomarkers and therapeutics for human disease.

Robert Raffai Image

Macrophage Exosomes in Atherosclerosis Control

Tuesday, 18 February 2020 at 09:00

Add to Calendar ▼2020-02-18 09:00:002020-02-18 10:00:00Europe/LondonMacrophage Exosomes in Atherosclerosis ControlEV-based Diagnostics, Delivery and Therapeutics in Coronado Island, CaliforniaCoronado Island,

Macrophages are a type of immune cell that display plasticity in inflammatory diseases including atherosclerosis. M1-macrophages contribute to inflammation and atherosclerosis acceleration while M2-macrophages display opposite effects to suppress and even regress atherosclerosis. More recently, macrophages have been shown to produce exosomes that can travel in the circulation and contribute to metabolic disorders including diabetes. But whether they impact atherosclerotic lesion dynamics is currently unknown. Our findings reveal that exosomes produced by M1-macropahges enhance inflammation and atherosclerosis acceleration while those produced by M2-like macrophages exert opposite effects. Thus, macrophage exosomes could serve as biomarkers and effectors of atherosclerosis disease severity and its resolution.

Add to Calendar ▼2020-02-17 00:00:002020-02-18 00:00:00Europe/LondonEV-based Diagnostics, Delivery and TherapeuticsEV-based Diagnostics, Delivery and Therapeutics in Coronado Island, CaliforniaCoronado Island,